Ligand ID: 40L Drugbank ID: DB09054(Idelalisib) Indication:Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 2acf | REPLICASEPOLYPROTEIN 1AB (SARS-COVTor2) | 5 / 12 | PRO C 184TYR D 295VAL D 329ASP D 196THR D 195 | 1.62A | 11.06 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 2cjr | NUCLEOCAPSID PROTEIN (SARS-COVTW1) | 5 / 12 | ILE A 305VAL A 351THR B 333MET B 323ILE A 358 | 1.54A | 8.78 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 2ga6 | ORF1A POLYPROTEIN (SARSr-CoV) | 5 / 12 | PRO S 107ILE S 99VAL S 116ASN S 85ILE S 55 | 1.65A | 10.38 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 2ozk | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 5 / 12 | ILE B 305ASP B 323THR B 274ASN B 74ILE B 295 | 1.67A | 14.77 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 2rhb | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARSr-CoV) | 5 / 12 | ILE D 305ASP D 323THR D 274ASN D 74ILE D 295 | 1.66A | 14.77 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 12 | PRO D 108ILE D 106TYR D 161VAL D 114ILE D 136 | 1.74A | 14.82 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 5c8u | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 12 | VAL D 136THR D 131ASN D 130ILE D 55ASP D 10 | 1.79A | 18.40 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 5f22 | NSP8 (SARSr-CoV) | 5 / 12 | ILE B 161TYR B 143VAL B 137ASP B 166ILE B 177 | 1.40A | 9.16 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 5 / 12 | VAL D 136THR D 131ASN D 130ILE D 55ASP D 10 | 1.75A | 19.39 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | VAL A 114THR A 229ASN A 230ILE A 226ASP B 454 | 1.48A | 21.47 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6crw | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 12 | PRO A 79ILE A 81TYR A 256ASP A 208THR A 31 | 1.30A | 21.57 | None | ||
![]() | 4XE0_A_40LA1101_0 (PHOSPHATIDYLINOSITOL4,5-BISPHOSPHATE3-KINASE CATALYTICSUBUNIT DELTAISOFORM) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 12 | ILE B 650TYR B 300VAL B 583ILE B 295ASP B 296 | 1.44A | 21.51 | None |